Ad-hoc | 29 August 2006 23:00

Rhein Biotech N.V.: Half year results

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Ad-Hoc-Announcement Rhein Biotech N.V., WKN: 919 544, Geregelter Markt: RBO Rhein Biotech N.V. reports 2006 Half Year results Maastricht, August 29, 2006 Rhein Biotech N.V. reports Half Year 2006 net sales of 9 million Euro. The EBIT was -1.2 million Euro. Rhein Biotech’s PROFIT in the Half Year 2006 amounted to 3.7 million Euro. The company’s cash position at the end of June 2006 was 25 million Euro. In March 2006 the Korea Food and Drug Administration (KFDA) has awarded licensure to Quinvaxem™, a fully liquid pentavalent vaccine co-developed with Chiron Corporation and produced in Korea. In April 2006 the group sold its shares in Rhein Biotech GmbH, Germany. Consolidated income statement for the half year ending June 30, 2006 IFRS The results are unaudited Amounts stated in EUR ‘000 June 30, 2006 June 30, 2005 Revenue 9 041 10 115 LOSS FROM OPERATIONS (EBIT) -1 186 -4 012 Net financing costs -1 022 282 Share of result of joint ventures 0 -3 Profit from discontinued operations 5 859 533 PROFIT (LOSS) FOR THE PERIOD 3 651 -3 200 End of the Ad Hoc Rhein Biotech is a member of the Crucell Group, a leading player for innovation in vaccines. For further information Crucell N.V. Paul Vermeij Director Investor Relations and Corporate Communications Tel. +31 (0)71 524 8718 p.vermeij@crucell.com (c)DGAP 29.08.2006 ————————————————————————— Language: English Issuer: Rhein Biotech N.V. Oude Maasstraat 47 6229 BC Maastricht Niederlande Phone: +31 433 56 78 9-0 Fax: +31 433 56 78 9-9 E-mail: patrik.richard@bernabiotech.com WWW: www.bernabiotech.com ISIN: NL0000230324 WKN: 919544 Indices: Listed: Geregelter Markt in Frankfurt (General Standard); Freiverkehr in Berlin-Bremen, Stuttgart, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————